Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Direct-acting Antivirals (DAA) are currently used in the treatment of chronic HCV infection. In patients with renal failure Glecaprevir/Pibrentasvir (genotype 1-6) is recommended for its safety and efficacy.
CASE PRESENTATION: Although these pharmacological characteristics, an adverse drug reaction (ADR) has been reported during Glecaprevir/Pibrentasvir treatment, such as the development of cholestatic jaundice in an elderly patient with chronic HCV (genotype 2) infection. At examination, patient was jaundiced associated with intense pruritus.
RESULTS: Ultrasound and laboratory biochemical tests excluded a liver failure (e.g. liver cancer, and liver lithiasis) or pancreatic cancer while Naranjo probability scale (score 6) suggested an association between cholestatic jaundice and Glecaprevir/Pibrentasvir administration. About 1 month after drug discontinuation, an improvement has been documented in both jaundice and pruritus, with a normalization in bilirubin levels (total bilirubin: 0.96 mg/dL), HCV-RNA was undetected also. It is worth mentioning that although we reported the development of cholestatic jaundice upon treatment with Glecaprevir/Pibrentasvir we recorded a clinical efficacy (HCV-RNA <15 IU/L) after 4 weeks from the beginning of the treatment, with a complete remission of clinical symptoms until 7 months after drug discontinuation.
CONCLUSION: These data support the clinical efficacy of Glecaprevir/Pibrentasvir association in elderly patients, despite the sub-optimal period of treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Current drug safety - 14(2019), 1 vom: 01., Seite 67-71 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Caroleo, Benedetto [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 10.05.2019 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1574886313666181116100452 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM290763479 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM290763479 | ||
003 | DE-627 | ||
005 | 20231225065423.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1574886313666181116100452 |2 doi | |
028 | 5 | 2 | |a pubmed24n0969.xml |
035 | |a (DE-627)NLM290763479 | ||
035 | |a (NLM)30444202 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Caroleo, Benedetto |e verfasserin |4 aut | |
245 | 1 | 0 | |a Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.05.2019 | ||
500 | |a Date Revised 04.12.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a BACKGROUND: Direct-acting Antivirals (DAA) are currently used in the treatment of chronic HCV infection. In patients with renal failure Glecaprevir/Pibrentasvir (genotype 1-6) is recommended for its safety and efficacy | ||
520 | |a CASE PRESENTATION: Although these pharmacological characteristics, an adverse drug reaction (ADR) has been reported during Glecaprevir/Pibrentasvir treatment, such as the development of cholestatic jaundice in an elderly patient with chronic HCV (genotype 2) infection. At examination, patient was jaundiced associated with intense pruritus | ||
520 | |a RESULTS: Ultrasound and laboratory biochemical tests excluded a liver failure (e.g. liver cancer, and liver lithiasis) or pancreatic cancer while Naranjo probability scale (score 6) suggested an association between cholestatic jaundice and Glecaprevir/Pibrentasvir administration. About 1 month after drug discontinuation, an improvement has been documented in both jaundice and pruritus, with a normalization in bilirubin levels (total bilirubin: 0.96 mg/dL), HCV-RNA was undetected also. It is worth mentioning that although we reported the development of cholestatic jaundice upon treatment with Glecaprevir/Pibrentasvir we recorded a clinical efficacy (HCV-RNA <15 IU/L) after 4 weeks from the beginning of the treatment, with a complete remission of clinical symptoms until 7 months after drug discontinuation | ||
520 | |a CONCLUSION: These data support the clinical efficacy of Glecaprevir/Pibrentasvir association in elderly patients, despite the sub-optimal period of treatment | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Direct-acting antiviral | |
650 | 4 | |a GFR | |
650 | 4 | |a HCV | |
650 | 4 | |a SVR | |
650 | 4 | |a cholestatic jaundice | |
650 | 4 | |a glecaprevir/pibrentasvir. | |
650 | 7 | |a Aminoisobutyric Acids |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Benzimidazoles |2 NLM | |
650 | 7 | |a Cyclopropanes |2 NLM | |
650 | 7 | |a Lactams, Macrocyclic |2 NLM | |
650 | 7 | |a Pyrrolidines |2 NLM | |
650 | 7 | |a Quinoxalines |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a pibrentasvir |2 NLM | |
650 | 7 | |a 2WU922TK3L |2 NLM | |
650 | 7 | |a Proline |2 NLM | |
650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
650 | 7 | |a Leucine |2 NLM | |
650 | 7 | |a GMW67QNF9C |2 NLM | |
650 | 7 | |a glecaprevir |2 NLM | |
650 | 7 | |a K6BUU8J72P |2 NLM | |
700 | 1 | |a Caroleo, Maria Cristina |e verfasserin |4 aut | |
700 | 1 | |a Cimellaro, Antonio |e verfasserin |4 aut | |
700 | 1 | |a Colangelo, Lidia |e verfasserin |4 aut | |
700 | 1 | |a Perticone, Maria |e verfasserin |4 aut | |
700 | 1 | |a Di Mizio, Giulio |e verfasserin |4 aut | |
700 | 1 | |a De Sarro, Giovambattista |e verfasserin |4 aut | |
700 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g 14(2019), 1 vom: 01., Seite 67-71 |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2019 |g number:1 |g day:01 |g pages:67-71 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886313666181116100452 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2019 |e 1 |b 01 |h 67-71 |